Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bone

Showing results (181-190 of 192) with videos related to

Pageof 20
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 24, 2015
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyS Papapoulos, K Lippuner, C Roux, et al.
The Lancet. Diabetes & Endocrinology|May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionHenry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 25, 2011
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos, Roland Chapurlat, Cesar Libanati, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2015
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trialBente L Langdahl, Christence Stubbe Teglbjærg, Pei-Ran Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll, Christence S Teglbjærg, Bente L Langdahl, et al.
German Medical Science : GMS E-Journal|July 15, 2010
Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI))K Reinhart, F M Brunkhorst, H-G Bone, et al.
Der Anaesthesist|April 24, 2010
[Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)]K Reinhart, F M Brunkhorst, H-G Bone, et al.
Pageof 20

Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 24, 2015
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyS Papapoulos, K Lippuner, C Roux, et al.
The Lancet. Diabetes & Endocrinology|May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionHenry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 25, 2011
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extensionSocrates Papapoulos, Roland Chapurlat, Cesar Libanati, et al.
The Journal of Clinical Endocrinology and Metabolism|August 28, 2013
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extensionHenry G Bone, Roland Chapurlat, Maria-Luisa Brandi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 22, 2015
A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trialBente L Langdahl, Christence Stubbe Teglbjærg, Pei-Ran Ho, et al.
The Journal of Clinical Endocrinology and Metabolism|June 23, 2012
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral densityEric Orwoll, Christence S Teglbjærg, Bente L Langdahl, et al.
German Medical Science : GMS E-Journal|July 15, 2010
Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI))K Reinhart, F M Brunkhorst, H-G Bone, et al.
Der Anaesthesist|April 24, 2010
[Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)]K Reinhart, F M Brunkhorst, H-G Bone, et al.
Pageof 20